Royalty Pharma plc trailing returns
How Royalty Pharma plc (RPRX) has performed over the last day, week, month and year, over 5 years, and since inception, through November 17, 2026 — price return and dividends side by side, with the worst drop inside each window.
Trailing returns by period#
Data provided bySource: Twelve DataTo 2026-11-17. Price return + dividends = total return. Worst drop: the deepest fall in the price from a high inside the window, and when it bottomed.
| Period | Price | DivsDividends | Total | Worst drop |
|---|---|---|---|---|
| Cumulative · the change over the window | ||||
| 1 day | +0.2% | +0.0% | +0.2% | — |
| 5 days | -1.1% | +0.3% | -0.8% | -2.1%Nov 16 |
| 1 month | +12.7% | +0.4% | +13.0% | -2.1%Nov 16 |
| YTD | +77.7% | +3.1% | +80.8% | -12.1%Oct 8 |
| Per year (CAGR) · the cumulative total return beneath | ||||
| 1 year | +75.4% | +3.0% | +78.4% CAGR | -12.1%Oct 2026 |
| 5 years | +10.1% | +2.7% | +12.8% CAGR+82.3% total | -45.6%Dec 2024 |
| Since 2020Since inception (2020) | +7.0% | +2.4% | +9.4% CAGR+77.5% total | -54.0%Dec 2024 |
Growth of RPRX#
Actual level with dividends reinvested (solid); dashed lines are each window's constant-rate path from start to today.
- 5 years+12.8%/year · +82.3%
Methodology#
Trailing returns measure from the closest close about N years before the latest close (2026-11-17). Cumulative return is the total change over the window; annualized return is the compound annual growth rate (CAGR), shown for windows of a year or more. Price return is the change in RPRX's closing price; total return reinvests dividends (from its split- and dividend-adjusted closes); the dividends column is the difference between the two. The worst drop is the largest fall in the closing price from a high to a later low inside the window, the way a drawdown is usually quoted. See the year-by-year returns for the calendar breakdown. Past performance does not predict future returns; not investment advice.
FAQ#
- What is Royalty Pharma plc's return since inception?
- Since 2020, Royalty Pharma plc (RPRX) has compounded at about +9.4% a year — +77.5% in total.
